so, too, would this be the case for hiv therapeutic vaccines. impressive results have been emerging recently. one company has shown that therapeutic vaccine, when used in monkeys that were intentionally highly infected with the monkey version of hiv, was able to achieve a functional cure in some of the monkeys. at two years, no detectible viral load was recorded, even in the most hard to reach reservoirs of these animals. this represents significant progress. another company has shown that his therapeutic vaccine reduced the viral set or baseline in patients significantly better than a placebo. this could offer an insurance policy to all people living with hiv who either have no access, as you mentioned, can't afford the treatments, no longer respond to them or simply stopped taking them. you can't stop taking a vaccine. once it's in you, it's in you. i want to make two last points. both of these cures, these beginning new cures, may fail because these companies do not have the money to really produce them. they do not have the money to produce

so too would this be the case for hiv therapeutic vaccines. impressive results have been emerging recently. one company based in gaithersburg has shown that therapeutic vaccine when used in monkeys that were intentionally highly infected with the monkey version of hiv was able to achieve a functional cure in some of the monkeys. at two years no detectable -- again no detectable viral load was recorded even in the hard to reach reservoirs of these ani l animals. another company base

these two companies who have the therapeutic vaccines, they don't have the money to produce it. one of them has a way. this works on human beings but you have to have money to get through the second level of trials the fda actually says they have something that actually works. because some of these medications you have to take some complicated regiments and it's worth it because it saves lives or prolongs it. it may be more realistic in people's lives. if i'm feeling healthy and i have hiv at an old level, i have to take care of the family, raise money, do things like that. the therapeutic vaccine is something that we may not have enough money to develop it. >> thank you. yes, dr. moon? >> i think this raises a very important point about prizes. it opens up the problem to be solved to a much broader population of potential solvers than other methods. and i think what he has reminded us is despite the therapy it does offer it's far from perfect. it's difficult to maintain, that there are, in fact, other areas that we could have conflict and mechanisms of innovation that encourage

these two companies had the therapeutic vaccines. they don't have the money to produce it. one of them has a -- works on human beings. you have to get enough money to get through the second level of trials for the fda so they could say we have something that works. some of the med casings we yo have to take complicated retch mens. it's worth it because it saves or prolongs life. it may fit into a more realic in people's lives. people who have hiv are not going to have take care of family, raise money, do things like that. you may not adhere to your regimen. the vaccine is a breakthrough i expect that kind of difference. we don't have enough money to develop it. >> okay. >> thank you. yes? >> i think he raises a important point on prices that we have not touched. the benefit of the mechanism it opens up a problem to be served to a broader population of potential solvers. i think what we has reminded us of despite the major therapy does offer it's for a from perfect. it's difficult to maintain. there are in fact, lots of area areas of ?irveg inquire that could yield -- that e

has shown that its therapeutic vaccine reduce the viral set of baseline in patients significantly better than a placebo. this could offer an insurance policy to all people living with hiv who either have no access, as you mentioned, can't afford the treatments, no longer respond to them or who simply stop taking them. you can't stop taking a vaccine once it's in you, it's in you. i want to make two other last points. both of these cures, these beginning to new cures may fail because these companies do not have the money to really produce them. they do not have the money to produce them. the one in norway is actually working in human beings, but they do not have the money to produce them. we need to rethink, as you said, as this bill says, how we actually get pharmaceutical companies to invest and incentivize companies to find new treatments. the national association of people with aids will be here as long as there are people living with hiv/aids. we want to be partners with senators, member ps of congress and industry representatives who are prepared to roll up our sleeves and make an h

the therapeutic vaccine could make that kind of difference, and we don't have enough money to develop. >> thank you. >> yes, dr. moon? >> i think mr. oldham raises a very important point about prices which we've not really touched on today which is the benefit of the price member anymore -- mechanism, in fact, opens up a problem to be solved to a much broader potential of solvers, and i think he has reminded us that despite the major advance that antiretroviral therapy does offer, far from perfect. it's difficult to maintain that there are, in fact, lots of other areas of scientific inquiry that could yield benefits and mechanisms for information that are, in fact, that encourage risk taking, that encourage breakthrough innovation are needed and that one of the strengths really, and i think there's a possibility of encouraging solvers from everywhere, from every corner to come forward and put their ideas on the table. >> okay. does anybody -- it's, we've been here for an hour and a half, and i don't want to keep you longer than necessary. is there anything that anyone wants to add or